Generic Skelaxin Moves Closer As King Loses Patent Case; Last Hurdle Is FDA
Executive Summary
Following a win in its patent case against King, Sandoz appears to have only one hurdle remaining before it can launch a generic of Skelaxin (metaxalone) - FDA approval of its ANDA
You may also be interested in...
Sandoz Tries An Authorized Generic Argument To Relaunch At-Risk Skelaxin
A temporary restraining order is blocking Sandoz's generic version of King's muscle relaxant, but CorePharma's launch of an authorized generic means the TRO should be lifted, Sandoz argues.
King Confident Of Embeda Opioid Approval In 2009; REMS Is The Final Hurdle
King Pharmaceuticals believes the FDA review of its abuse-resistant painkiller Embeda is "substantially complete," and that the company will be able to launch the drug in 2009, CEO Brian Markison assured investors during an earnings call Feb. 26
King Confident Of Embeda Opioid Approval In 2009; REMS Is The Final Hurdle
King Pharmaceuticals believes the FDA review of its abuse-resistant painkiller Embeda is "substantially complete," and that the company will be able to launch the drug in 2009, CEO Brian Markison assured investors during an earnings call Feb. 26